

Zachary J Reitman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11177136/zachary-j-reitman-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

3,090
citations

16
h-index

28
g-index

28
ext. papers

3,536
ext. citations

8.6
avg, IF

4.58
L-index

#	Paper	IF	Citations
25	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6021-6	11.5	968
24	Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012 , 3, 709-22	3.3	439
23	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 932-41	9.7	372
22	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 3270-5	11.5	340
21	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. <i>Oncotarget</i> , 2014 , 5, 1515-25	3.3	187
20	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. <i>Nature Genetics</i> , 2014 , 46, 726-30	36.3	116
19	Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. <i>Cancer Research</i> , 2013 , 73, 496-501	10.1	99
18	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. <i>PLoS ONE</i> , 2011 , 6, e16812	3.7	92
17	The genome-wide mutational landscape of pituitary adenomas. <i>Cell Research</i> , 2016 , 26, 1255-1259	24.7	81
16	Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. <i>Journal of Biological Chemistry</i> , 2014 , 289, 23318-28	5.4	64
15	IDH1 and IDH2: not your typical oncogenes. <i>Cancer Cell</i> , 2010 , 17, 215-6	24.3	60
14	The genetic landscape of anaplastic astrocytoma. <i>Oncotarget</i> , 2014 , 5, 1452-7	3.3	59
13	Exomic sequencing of four rare central nervous system tumor types. <i>Oncotarget</i> , 2013 , 4, 572-83	3.3	57
12	IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 398, 585-7	3.4	45
11	Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in <i>Drosophila</i> . <i>Blood</i> , 2015 , 125, 336-45	2.2	25
10	New Directions in the Treatment of Glioblastoma. <i>Seminars in Neurology</i> , 2018 , 38, 50-61	3.2	23
9	Enzyme redesign guided by cancer-derived IDH1 mutations. <i>Nature Chemical Biology</i> , 2012 , 8, 887-9	11.7	14

8	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018 , 28, 694-699	2.9	12
7	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018 , 126, 511-518	5.3	11
6	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. <i>European Journal of Medicinal Chemistry</i> , 2016 , 119, 218-30	6.8	8
5	A Need for More Molecular Profiling in Brain Metastases.. <i>Frontiers in Oncology</i> , 2021 , 11, 785064	5.3	1
4	Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients. <i>Seminars in Radiation Oncology</i> , 2022 , 32, 3-14	5.5	1
3	Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 ,	4	1
2	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.. <i>Nature Communications</i> , 2022 , 13, 604	17.4	0
1	Malignant Glioma: Isocitrate Dehydrogenases 1 and 2 Mutations 2011 , 53-62		